Form 4: SAB Biotherapeutics CFO, Lucy To, Acquires Stock Options
SEC Form 4 Filing
Lucy To, CFO of SAB Biotherapeutics, acquired options to purchase 125,000 shares of common stock on August 12, 2024.
Summary
- Lucy To, the Chief Financial Officer of SAB Biotherapeutics, Inc. (SABS), filed a Form 4 on August 13, 2024.
- The filing reports a transaction that occurred on August 12, 2024, where Ms. To acquired options to purchase 125,000 shares of common stock.
- These options are part of the company's 2021 Omnibus Equity Incentive Plan, as amended.
- The exercise price of the options is $2.35 per share.
- The options vest over a four-year period, starting with 1/4 vesting on August 12, 2025 (the one-year anniversary of her start date as CFO), and the remainder vesting in equal monthly installments over the following three years.
- The options expire on August 12, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.
Positives
- The grant of stock options to the CFO aligns her interests with those of the shareholders, incentivizing her to improve the company's performance.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Granting stock options to executives is a standard practice in the biotech industry.
- The vesting schedule of four years with a one-year cliff is also typical.
- Comparing the size of the grant to similar companies would require further analysis of SAB Biotherapeutics' compensation policies and market capitalization.
Stakeholder Impact
- Shareholders may view the option grant as a positive sign, aligning management's interests with theirs.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2021 | Company's 2021 Omnibus Equity Incentive Plan, as amended. |
| 08/12/2024 | Date of transaction: CFO acquired stock options. |
| 08/12/2025 | First vesting date for 1/4 of the options. |
| 08/12/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.